Gennex Laboratories Limited (BOM:531739)
India · Delayed Price · Currency is INR 15.76
+0.09 (0.57%)
At close: Nov 14, 2025
Gennex Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 1,495 | 1,379 | 867.14 | 656.03 | 612.14 | 596.49 | Upgrade |
Other Revenue | 0.41 | - | - | - | - | - | Upgrade |
| 1,495 | 1,379 | 867.14 | 656.03 | 612.14 | 596.49 | Upgrade | |
Revenue Growth (YoY) | 32.86% | 59.03% | 32.18% | 7.17% | 2.62% | 6.08% | Upgrade |
Cost of Revenue | 1,083 | 978.18 | 493.58 | 402.92 | 384.15 | 359.29 | Upgrade |
Gross Profit | 411.78 | 400.85 | 373.57 | 253.11 | 227.98 | 237.2 | Upgrade |
Selling, General & Admin | 91.19 | 88.01 | 78.91 | 80.63 | 73.48 | 74.36 | Upgrade |
Other Operating Expenses | 142.62 | 142.46 | 120.79 | 122.77 | 99.74 | 96.23 | Upgrade |
Operating Expenses | 253.91 | 250.37 | 223.38 | 212.6 | 181.1 | 179.4 | Upgrade |
Operating Income | 157.87 | 150.48 | 150.18 | 40.51 | 46.88 | 57.8 | Upgrade |
Interest Expense | -40.49 | -36.08 | -30.76 | -13.54 | -8.77 | -7.44 | Upgrade |
Interest & Investment Income | 95.71 | 95.71 | 37.95 | 26.61 | 9 | 0.54 | Upgrade |
Currency Exchange Gain (Loss) | 2.39 | 2.39 | 1.76 | 4.15 | 3.79 | 3.44 | Upgrade |
Other Non Operating Income (Expenses) | 1.68 | 1.68 | -0 | 5.5 | -0 | - | Upgrade |
EBT Excluding Unusual Items | 217.16 | 214.18 | 159.13 | 63.23 | 50.9 | 54.34 | Upgrade |
Gain (Loss) on Sale of Assets | -0.21 | -0.21 | 5.79 | 0.5 | 0.03 | - | Upgrade |
Other Unusual Items | - | - | - | - | - | -3.71 | Upgrade |
Pretax Income | 216.95 | 213.97 | 164.92 | 63.73 | 50.94 | 50.62 | Upgrade |
Income Tax Expense | 30.75 | 32.75 | 33.17 | 14.52 | 11.7 | 10.24 | Upgrade |
Net Income | 185.52 | 181.23 | 131.75 | 49.21 | 39.23 | 40.38 | Upgrade |
Net Income to Common | 185.52 | 181.23 | 131.75 | 49.21 | 39.23 | 40.38 | Upgrade |
Net Income Growth | 7.30% | 37.55% | 167.74% | 25.43% | -2.85% | 117.53% | Upgrade |
Shares Outstanding (Basic) | 235 | 227 | 187 | 146 | 127 | 127 | Upgrade |
Shares Outstanding (Diluted) | 238 | 231 | 217 | 154 | 127 | 127 | Upgrade |
Shares Change (YoY) | -4.65% | 6.81% | 40.48% | 21.94% | - | - | Upgrade |
EPS (Basic) | 0.79 | 0.80 | 0.71 | 0.34 | 0.31 | 0.32 | Upgrade |
EPS (Diluted) | 0.78 | 0.78 | 0.61 | 0.32 | 0.31 | 0.32 | Upgrade |
EPS Growth | 12.53% | 28.78% | 90.60% | 2.86% | -2.78% | 117.39% | Upgrade |
Free Cash Flow | -943.45 | -197.44 | -466.86 | -161.1 | 103.14 | -15.16 | Upgrade |
Free Cash Flow Per Share | -3.96 | -0.85 | -2.15 | -1.04 | 0.81 | -0.12 | Upgrade |
Gross Margin | 27.54% | 29.07% | 43.08% | 38.58% | 37.24% | 39.77% | Upgrade |
Operating Margin | 10.56% | 10.91% | 17.32% | 6.17% | 7.66% | 9.69% | Upgrade |
Profit Margin | 12.41% | 13.14% | 15.19% | 7.50% | 6.41% | 6.77% | Upgrade |
Free Cash Flow Margin | -63.11% | -14.32% | -53.84% | -24.56% | 16.85% | -2.54% | Upgrade |
EBITDA | 177.96 | 170.38 | 173.86 | 49.7 | 54.76 | 66.6 | Upgrade |
EBITDA Margin | 11.91% | 12.35% | 20.05% | 7.58% | 8.95% | 11.17% | Upgrade |
D&A For EBITDA | 20.1 | 19.91 | 23.68 | 9.19 | 7.88 | 8.81 | Upgrade |
EBIT | 157.87 | 150.48 | 150.18 | 40.51 | 46.88 | 57.8 | Upgrade |
EBIT Margin | 10.56% | 10.91% | 17.32% | 6.17% | 7.66% | 9.69% | Upgrade |
Effective Tax Rate | 14.17% | 15.30% | 20.11% | 22.79% | 22.98% | 20.23% | Upgrade |
Revenue as Reported | 1,599 | 1,483 | 916.2 | 695.56 | 625.95 | 601.73 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.